{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-22-001853","form_type":"8-K","ticker":"XBIO","cik":"0001534525","company_name":"Xenetic Biosciences, Inc.","filed_at":"2022-03-23T23:59:59+00:00","discovered_at":"2026-05-14T18:04:06.899345+00:00","generated_at":"2026-06-26T19:39:31.265811+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Xenetic reports FY2021 net loss of $5.6M; royalty revenue up 166% to $1.2M","bullets":["Net loss for FY2021 was approx $5.6M; R&D expenses rose to $3.2M (vs $1.7M in 2020) on XCART investment.","Cash at year-end $18.2M; working capital $17.3M, up from $11.4M in 2020.","Royalty payments from PolyXen platform totaled $1.2M, up 166% YoY, from Takeda sublicensee product launches.","XCART program advancing toward IND-enabling studies; U.S. patent for co-administration with personalized vaccine issued."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-22-001853","json":"https://secwatch.observer/filing/0001683168-22-001853.json","markdown":"https://secwatch.observer/filing/0001683168-22-001853.md","text":"https://secwatch.observer/filing/0001683168-22-001853.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534525/000168316822001853/0001683168-22-001853-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534525/000168316822001853/xenetic_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T19:39:31.265811+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}